TY - JOUR
T1 - Low-density lipoprotein particles and risk of intracerebral haemorrhage in subjects with cerebrovascular disease
AU - Campbell, Duncan J.
AU - Neal, Bruce C.
AU - Chalmers, John P.
AU - Colman, Samuel A.
AU - Jenkins, Alicia J.
AU - Kemp, Bruce E.
AU - Patel, Anushka
AU - Macmahon, Stephen W.
AU - Woodward, Mark
N1 - Funding Information:
This study was funded by grants from the NIH (5 R01 HL071685), the National Health and Medical Research Council of Australia, and by the National Heart Foundation of Australia. D.J.C and B.C.N. are recipients of Career Development Awards, and A.J.J. is the recipient of a Clinical Research Fellowship from the National Heart Foundation of Australia. B.E.K. is an Australian Research Council Federation Fellow. PROGRESS was funded by grants from Servier, the Health Research Council of New Zealand, and the National Health and Medical Research Council of Australia. D.J.C. has had research contracts with Solvay Pharmaceutical Company and Novartis in the past 5 years and has been a member of an advisory board for Novartis; J.P.C. and S.W.M. hold research grants from Servier, as Chief Investigators for PROGRESS and ADVANCE, administered by the University of Sydney; J.P.C., A.P., B.C.N., M.W. and S.W.M. have also received honoraria from Servier for speaking in relation to PROGRESS and/or ADVANCE at scientific meetings.
PY - 2007/6
Y1 - 2007/6
N2 - Only limited data are available for risk factors for intracerebral haemorrhage (ICH) in subjects with established cerebrovascular disease. We performed a nested case-control study of participants of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). This was a randomized, placebo-controlled trial that established the beneficial effects of blood pressure lowering in 6105 patients with cerebrovascular disease. Each of 41 subjects who experienced ICH during a mean follow-up of 3.9 years was matched to 1-3 control subjects. Lipoprotein particles and other plasma markers were measured in baseline blood samples from PROGRESS participants. In comparison with control subjects, ICH cases had increased mean low-density lipoprotein (LDL) diameter (P=0.04) and increased large LDL particle concentration (P=0.03). The odds ratio (adjusted for regression dilution bias) for ICH risk with 10 mmHg increase in systolic blood pressure (SBP) was 1.45 (95% confidence interval: 1.01-2.09, P=0.05), with a 1 nm increase in mean LDL diameter it was 2.15 (95% confidence interval: 0.97-4.77, P=0.06), and with 100 nmol/l increase in large LDL particle concentration it was 1.18 (95% confidence interval: 0.98-1.43, P=0.08). Plasma levels of C-reactive protein (CRP), soluble vascular cell adhesion molecule 1 (sVCAM-1), homocysteine, amino-terminal-pro-B-type natriuretic peptide (NT-proBNP), and renin were not associated with ICH risk. SBP predicted ICH risk in subjects with cerebrovascular disease, whereas CRP, sVCAM-1, homocysteine, NT-proBNP, and renin did not predict ICH risk. The trends for prediction of ICH risk by mean LDL particle diameter and large LDL particle concentration are hypothesis generating and require confirmation in larger studies.
AB - Only limited data are available for risk factors for intracerebral haemorrhage (ICH) in subjects with established cerebrovascular disease. We performed a nested case-control study of participants of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). This was a randomized, placebo-controlled trial that established the beneficial effects of blood pressure lowering in 6105 patients with cerebrovascular disease. Each of 41 subjects who experienced ICH during a mean follow-up of 3.9 years was matched to 1-3 control subjects. Lipoprotein particles and other plasma markers were measured in baseline blood samples from PROGRESS participants. In comparison with control subjects, ICH cases had increased mean low-density lipoprotein (LDL) diameter (P=0.04) and increased large LDL particle concentration (P=0.03). The odds ratio (adjusted for regression dilution bias) for ICH risk with 10 mmHg increase in systolic blood pressure (SBP) was 1.45 (95% confidence interval: 1.01-2.09, P=0.05), with a 1 nm increase in mean LDL diameter it was 2.15 (95% confidence interval: 0.97-4.77, P=0.06), and with 100 nmol/l increase in large LDL particle concentration it was 1.18 (95% confidence interval: 0.98-1.43, P=0.08). Plasma levels of C-reactive protein (CRP), soluble vascular cell adhesion molecule 1 (sVCAM-1), homocysteine, amino-terminal-pro-B-type natriuretic peptide (NT-proBNP), and renin were not associated with ICH risk. SBP predicted ICH risk in subjects with cerebrovascular disease, whereas CRP, sVCAM-1, homocysteine, NT-proBNP, and renin did not predict ICH risk. The trends for prediction of ICH risk by mean LDL particle diameter and large LDL particle concentration are hypothesis generating and require confirmation in larger studies.
KW - C-reactive protein
KW - amino-terminal-pro-B-type natriuretic peptide
KW - cerebrovascular disorders
KW - homocysteine
KW - intracerebral haemorrhage
KW - lipoprotein
KW - renin
KW - risk factor
KW - soluble vascular cell adhesion molecule 1
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=34250634786&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250634786&partnerID=8YFLogxK
U2 - 10.1097/HJR.0b013e328010f275
DO - 10.1097/HJR.0b013e328010f275
M3 - Article
C2 - 17568241
AN - SCOPUS:34250634786
SN - 2047-4873
VL - 14
SP - 413
EP - 418
JO - European Journal of Preventive Cardiology
JF - European Journal of Preventive Cardiology
IS - 3
ER -